OG716

OG716 is a **novel lantibiotic** developed as a therapeutic agent targeting *Clostridioides difficile* (formerly *Clostridium difficile*) infection (CDI). It is an engineered variant derived from mutacin 1140 (MU1140), a member of the lantibiotic class, selected from a large library for superior potency, solubility, and pharmacological stability. The main mechanism of action is inhibition of **cell wall biosynthesis** via binding to **lipid II** at a unique site distinct from vancomycin’s binding site. OG716 demonstrates excellent **oral efficacy**, robust survival in animal CDI models (including 100% survival with no relapse at 3 weeks in the Golden Syrian hamster model), and favorable safety and compartmentalization in the gastrointestinal tract with negligible systemic exposure. It shows low cytotoxicity, low off-target effects, and a pharmacological profile that supports further clinical development for CDI[1][2][3][4][5][6][7][8].